A Medical Device Daily

Candela (Wayland, Massachusetts) reported that it will acquire all share capital of Inolase (Netanya, Israel), in a cash transaction valued at about $16.5 million, excluding certain earn-out performance targets and royalties. The acquisition is expected to be accretive to earnings within 18 months, the company said.

Inolase is the developer of Pneumatic Skin Flattening (PSF) technology, a vacuum-driven system designed to provide pain-free enhancements to laser and light-based devices.

PSF is FDA-approved for use in hair removal when used with lasers or intense pulse light (IPL) systems and is CE-marked. It is also under investigation for use in several other applications, including non-ablative skin rejuvenation, skin tightening and treatment of pigmented lesions and tattoos.

Candela said that PSF is being adapted for use by a majority of the worldwide installed base of more than 70,000 lasers and IPLs, as estimated by Millenium Research. It said that it plans to market PSF to work with Candela’s installed base of equipment beginning this fall.

“Inolase is a perfect strategic fit for Candela,” said Gerard Puorro, president/CEO of Candela. “As the market leader in laser and light-based devices for the aesthetic market, we can immediately leverage our distribution channels to roll out this exciting new offering that has been shown to reduce the pain associated with laser and light-based treatments. Pain is the most significant inhibitor to broad consumer adoption of these treatments. By reducing the pain, we can also eliminate the need for costly and time consuming analgesic creams.”

With the roll-out of PSF to existing customers, Puorro said the company plans to offer PSF as an option on many of its new product offerings.

Candela also reported the creation of an Emerging Opportunities unit, designed to engage develop and acquire technologies and new product offerings.

Under the direction of Catherine Kniker, newly promoted to senior VP, corporate strategic development, this unit will pursue new applications, including home-based products.

“We are excited about organizing our resources to bring more focus on new growth opportunities,” said Kniker. “Inolase will give us strong momentum right from the start. We see a lot of potential for integrating PSF into our complete product road map.”

As part of Inolase deal, Knicker said the company also acquired additional intellectual property that, when implemented, will remove the inadvertent threat of injury to the eye from lasers while maintaining treatment efficacy.

“This technology paves the way for Candela to develop safe, over-the-counter devices for home use across a number of applications,” Knicker said.

The company also reported the creation of a Customer Operations Division, comprising Sales, Marketing, Field Service and Customer Service. These three units will be North America, Japan and International, all reporting to Puorro.

Lifeline Biotechnologies (Reno, Nevada) reported that the company has reached an agreement with Solos Endoscopy (Boston) to reacquire ownership, including all rights, to continue the development and marketing of the First Warning System, designed to assist in early detection of breast cancer.

“An agreement has been reached with Solos Endoscopy whereby Lifeline will pursue the development and testing of the First Warning System as a very high priority,” said Jim Holmes, CEO of Lifeline. “We’re extremely excited to have obtained the First Warning System, which we had sold to Solos last year. The company has identified promising new technologies which could assist in the interpretation of patient data and lead to much earlier breast cancer detection than any existing technology.”

Lifeline’s technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions.

Wyndgate Technologies (Denver), a division of Global Med Technologies, said that Caldwell Memorial Hospital (CMH; Lenoir, North Carolina) has signed an agreement to license Wyndgate’s SafeTrace Tx transfusion management software. Terms were not disclosed.

This represents Wyndgate’s 15th installed donor or transfusion system throughout the Carolinas.

Global Med provides information management software products and services to healthcare. Wyndgate Technologies is a supplier of information management systems to U.S. and international blood centers and hospital transfusion centers.

MedServe (Houston), through its operating subsidiaries Enserv and Envirosolve, said it has completed another round of acquisitions — in Tennessee, Oklahoma and Michigan — as part of continued consolidation of local and regional operators in the medical waste industry. The financial terms of the acquisitions were not disclosed.

MedServe said it now expands presence for the first time into the Great Lakes region and further into Southeastern markets.

MedServe’s management has now completed 13 acquisitions in less than two years in its “quest to become the second largest company in the medical waste management sector.”

MedServe provides medical waste management solutions including mobile medical waste treatment services, waste liability management, waste minimization programs, sharps tracking and retrieval, and medical waste collection, transport, treatment and disposal.